LCAR-AIO

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameLCAR-AIO
Drug Alias NameCD19/CD20/CD22 CAR-T cell therapyLCAR-AIOVHH CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-CD19Anti-CD20Anti-CD22
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20CD22
Therapy Area/IndicationsMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseAutoimmune DiseasesLupus Erythematosus, Systemic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Legend Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Legend Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseLupus Erythematosus, SystemicNeuromyelitis Optica +[6] 
Inactive IndicationsAutoimmune DiseasesLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A